Laboratorios Rubió Secures €4M to Accelerate Global Access to Life-Changing Medications

Laboratorios Rubió is excited to announce that we have successfully raised 4,000,000, a major milestone that will further our mission of making essential medications accessible to everyone, regardless of the rarity of their condition. For over 50 years, our company has been a beacon of innovation and compassion within the pharmaceutical industry, pioneering treatments for low-prevalence diseases since our founding in 1968. One of our most notable achievements is the launch of the first ADHD medication in Spain—a breakthrough that set the stage for our continued commitment to transforming healthcare. With a robust portfolio of over a dozen benchmark medications and expanding ventures into diagnostics and clinical nutrition, our family-owned company stands firmly on the pillars of in-house production, relentless R&D investment, and strategic international collaborations backed by esteemed certifications such as the FDA. The recent injection of funds will be strategically invested to escalate our global footprint and fortify our R&D capabilities, ensuring that we continue to lead innovation in both existing and emerging health areas. Our vision is clear: to deepen our research initiatives, enhance manufacturing processes, and nurture collaborative partnerships that open new avenues for medical breakthroughs. By doubling down on these priorities, we are not only investing in the future of Laboratorios Rubió, but also in the health and well-being of communities around the world. This funding round is a testament to the trust and confidence our investors have in our long-term vision and our unwavering commitment to improving quality of life by breaking barriers in medicine. #WeAreRubió